火爆医药产业的抗体偶联药物(ADC)市场赛道再度迎来重磅交易。先声药业日前发布公告,公司附属公司江苏先声再明医药有限公司与法国益普生(Ipsen)签订独家授权许可协议。根据协议,益普生将获得由先声再明开发的ADC在研产品SIM0613在大中华区以外地区的全球独家开发、生产及商业化权利。据悉,先声再明可获得高达10.6亿美元的交易总付款,包括4500万美元预付款、开发、监管和商业里程碑付款,并且可以...
Source Link火爆医药产业的抗体偶联药物(ADC)市场赛道再度迎来重磅交易。先声药业日前发布公告,公司附属公司江苏先声再明医药有限公司与法国益普生(Ipsen)签订独家授权许可协议。根据协议,益普生将获得由先声再明开发的ADC在研产品SIM0613在大中华区以外地区的全球独家开发、生产及商业化权利。据悉,先声再明可获得高达10.6亿美元的交易总付款,包括4500万美元预付款、开发、监管和商业里程碑付款,并且可以...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.